Expertise in
4
conditions

Dr. Ravi Madan

Hematology | Oncology
Valid For US Civil Service Employee On
10 Center Dr Apt 608, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
4
conditions
Valid For US Civil Service Employee On
10 Center Dr Apt 608, 
Bethesda, MD 

Overview

Ravi Madan is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland.

Dr. Madan is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Chordoma, Medullary Thyroid Carcinoma, Orchiectomy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 191 peer reviewed articles and participating in 5 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NJ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Valid for US Civil Service Employee on
10 Center Dr Apt 608, Bethesda, MD 20892

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
Enrollment Status: Recruiting
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drugs: ADT, Prednisone, M7824, Docetaxel, M9241
Study Phase: Phase 1/Phase 2
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Enrollment Status: Recruiting
Publish Date: April 06, 2026
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer
Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 16, 2026
Intervention Type: Drug
Study Drugs: Radium-223, 18F Sodium Fluoride
Study Phase: Phase 2
A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer
A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Biological
Study Drug: GI-6207
Study Phase: Phase 2
A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
Enrollment Status: Completed
Publish Date: May 07, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

191 Total Publications

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: March 13, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology

Office

9609 Medical Center Dr, 
Bethesda, MD 
 (8.0 miles away)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Savage is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology
Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology

Office

9609 Medical Center Dr Rm 6E452, 
Rockville, MD 
 (15.9 miles away)
240-276-7239
Languages Spoken:
English

Blanche Alter is a Hematologist and an Oncologist practicing medicine in Rockville, Maryland. Dr. Alter is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Aase Syndrome, Dyskeratosis Congenita, Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
18
conditions
Dr. Taofeek Owonikoko
Hematology | Oncology
Expertise in
18
conditions
Dr. Taofeek Owonikoko
Hematology | Oncology

Office

22 S Greene St # 9, 
Baltimore, MD 
 (34.5 miles away)
410-328-6841
Languages Spoken:
English
See accepted insurances

Taofeek Owonikoko is a Hematologist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Frequently Asked Questions about Dr. Ravi Madan

How do I make an appointment with Dr. Ravi Madan?

You can book an appointment with Dr. Ravi Madan by calling their office at 301-496-4916. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ravi Madan a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ravi Madan is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ravi Madan specialize in?

While Dr. Ravi Madan is a Hematology, they have specific expertise in Prostate Cancer, Chordoma, and Medullary Thyroid Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ravi Madan participate in research or clinical trials?

Yes. Dr. Ravi Madan has published 191 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Ravi Madan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Madan's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile